Anavex Life Sciences Corp.

Company: Anavex Life Sciences Corp.
Ticker: AVXL
Class Action Period: November 26, 2025 – August 28, 2026

61 Days Left Lead Plaintiff Deadline: November 30, 2026

Submit Your Information

If you suffered a loss on your Anavex Life Sciences Corp. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Last Name*

Email*

Phone*

City

State

Country

Total # of shares

First Purchase Date

Last Purchase Date

Estimated Loss Range

Check here if you still hold any shares.

Check here if you are a current or former employee of the company.

Check here if you purchased any shares before November 26, 2025

Additional Comments

Background

On May 11, 2026, the Company filed with the SEC a notification of late filing which disclosed it had “terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy.”

On this news, Anavex stock fell $0.18 per share, or 5.55%, to close at $3.06 on May 12, 2026, thereby injuring investors.

On August 28, 2026, Anavex filed an Amended 2025 Annual Report with the SEC. The report stated, in part, that as a result of a review by the Special Committee, management, in consultation with the Audit Committee of the Board, “concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025” and that “the Company’s disclosure controls and procedures were not effective.”

On this news, Anavex stock fell $0.19 per share, or 6.35%, to close at $2.80 on August 31, 2026, thereby injuring investors further.

Submit Your Information